Table 2 Cox regression analysis for overall survival and recurrence-free survival

From: GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma

 

Univariate analysis

Multivariate analysis

Variable

HR

95% CI

P -value

HR

95% CI

P -value

(A) Overall survival

T stage

 T3–4 vs T1–2

19.627

11.045–34.879

<0.001

8.747

4.249–18.005

<0.001

Lymph-node status

 N1–2 vs N0

15.946

9.294–27.358

<0.001

6.496

3.440–12.269

<0.001

Distant metastasis

 M1 vs M0

12.775

6.928–23.555

<0.001

2.580

1.350–4.930

0.004

Histopathologic subtype

 ccRCC vs other type

3.144

1.259–7.849

0.014

1.257

0.471–3.351

0.648

Fuhman grade

 G3-4 vs G1–2

8.160

4.876–13.656

<0.001

2.006

1.071–3.756

0.030

GOLPH3 expression

 High vs low

5.755

2.923–11.330

<0.001

5.341

2.496–11.428

<0.001

(B) Recurrence-free survival

T stage

 T3–4 vs T1–2

16.920

9.427–30.371

<0.001

7.759

3.671–16.399

<0.001

Lymph-node status

 N1–2 vs N0

21.321

11.580–39.256

<0.001

7.946

3.502–18.032

<0.001

Histopathologic subtype

 ccRCC vs other type

2.824

1.121–7.115

0.028

1.802

0.691–4.703

0.229

Fuhman grade

 G3–4 vs G1–2

7.754

4.442–13.535

<0.001

2.260

1.120–4.561

0.023

GOLPH3 expression

 High vs low

3.611

1.9233–6.780

<0.001

4.416

2.193–8.894

<0.001

  1. Abbreviations: 95% CI=95% confidence interval; ccRCC=clear cell RCC; GOLPH3=Golgi phosphoprotein 3; HR=hazard ratio.
Back to article page